BE1024512B1 - Composition for use in the treatment of Psoriasis - Google Patents

Abstract

The present invention relates to a composition for use in the treatment of Psoriasis, said composition comprising: - at least one antioxidant, in particular at least one superoxide dismutase antioxidant (SOD), - turmeric or at least one extract of Turmeric, in particular Curcuma longa or an extract of Curcuma longa, and - Boswellia or at least one extract of Boswellia, in particular Boswellia serrata or at least one extract of Boswellia serrata.

Description

economy

1024512 Bl

FPS Economy, SMEs, Middle Classes & Energy Intellectual Property Office

Issue date: 03/21/2018

PATENT

Priority date:

International classification: A61K 36/9066, A61K 38/06, A61K 38/44, A61K 31/00, A61K 36/324, A23L 33/105, A61P 17/06

Deposit number: BE2017 / 5028

Filing date: 01/17/2017

Holder:

DYNA + SARL 1930, LUXEMBOURG Luxembourg

Inventor:

MOTTE François 1380 LAS NE Belgium

WYVEKENS Guy 1380 LAS NE Belgium

Composition for use in the treatment of Psoriasis

The present invention relates to a composition intended for use in the treatment of Psoriasis, said composition comprising: - at least one antioxidant, in particular at least one antioxidant of superoxide dismutase (SOD) type, - Turmeric or at least one extract of Turmeric, in particular Curcuma longa or an extract of Curcuma longa, and - from Boswellia or at least one extract from Boswellie, in particular Boswellia serrata or at least one extract from Boswellia serrata.

BELGIAN INVENTION PATENT

FPS Economy, SMEs, Middle Classes & Energy

Publication number: 1024512 Deposit number: BE2017 / 5028

Intellectual Property Office International Classification: A61K 36/9066 A61K 38/06 A61K 38/44 A61K 31/00 A61K 36/324 A23L 33/105 A61P 17/06 Date of issue: 21/03/2018

The Minister of the Economy,

Having regard to the Paris Convention of March 20, 1883 for the Protection of Industrial Property;

Considering the law of March 28, 1984 on patents for invention, article 22, for patent applications introduced before September 22, 2014;

Given Title 1 “Patents for invention” of Book XI of the Code of Economic Law, article XI.24, for patent applications introduced from September 22, 2014;

Having regard to the Royal Decree of 2 December 1986 relating to the request, the issue and the maintenance in force of invention patents, article 28;

Considering the patent application received by the Intellectual Property Office on 17/01/2017.

Whereas for patent applications falling within the scope of Title 1, Book XI of the Code of Economic Law (hereinafter CDE), in accordance with article XI. 19, §4, paragraph 2, of the CDE, if the patent application has been the subject of a search report mentioning a lack of unity of invention within the meaning of the §ler of article XI.19 cited above and in the event that the applicant does not limit or file a divisional application in accordance with the results of the search report, the granted patent will be limited to the claims for which the search report has been drawn up.

Stopped :

First article. - It is issued to

DYNA + SARL, Avenue de la Liberté 16A, 1930 LUXEMBOURG Luxembourg;

represented by

GEVERS PATENTS, Holidaystraat 5, 1831, DIEGEM;

a 20-year Belgian invention patent, subject to payment of the annual fees referred to in article XI.48, §1 of the Code of Economic Law, for: Composition intended for use in the treatment of Psoriasis .

INVENTOR (S):

MOTTE François, Route d'Ottignies 86, 1380, LASNE;

WYVEKENS Guy, Rue Haute 30, 1380, LASNE;

PRIORITY (S):

DIVISION:

divided from the basic application: filing date of the basic application:

Article 2. - This patent is granted without prior examination of the patentability of the invention, without guarantee of the merit of the invention or of the accuracy of the description thereof and at the risk and peril of the applicant (s) ( s).

Brussels, 03/21/2018, By special delegation:

B E2017 / 5028

Composition intended to be yfflbé® in the treatment of Psoriasis

The present invention relates to a composition for use in the treatment of Psoriasis.

Psoriasis is linked to chronic inflammation of the skin and occurs in people who are genetically predisposed, usually due to an additional physical or psychological factor. In other words and more specifically, Psoriasis is a common chronic erythematosquamous dermatosis. This pathology is characterized by a disorder of epidermal homeostasis (hyperproliferation and disorders of keratinocyte differentiation) as well as by complex dermo-epidermal inflammatory phenomena responsible for an accelerated renewal of the epidermis induced by extrakeratinocyte proliferation factors or by intrinsic keratinocyte abnormalities.

Extrakeratinocyte factors could be produced by neutrophils (which migrate in the stratum corneum and participate in the histological signs of Psoriasis) or by CD4 lymphocytes which, after actlvanon by classical antigens or activated superantigens would produce various cytokines stimulating the turnover of keratinocytes .

Concerning the intrakeratinocyte factors, various anomalies of tmnsduction of the membrane to the nucleus have been described in Psoriasis (pathway of protein kinase A, C, cyclic nucleotides, ...). There is an increase in the expression of different receptors to EGF (Epidermal Growth Factor), various anomalies in the adhesion molecules, a disturbance of various growth factors and differentiation of keratinocytes (TGF alpha, IL-8,. ..) and various anomalies in the genes involved in the response to vitamin D and vitamin A which participate in epidermal proliferation and differentiation.

B E2017 / 5028

Besides the extrakeratinocytic factors and the intrarakatinocytic factors, etiological factors come out! also highlighted for Psoriasis, such as environmental factors, genetic predispositions, infectious factors, taking certain medications, psychological factors and aggravating factors such as tobacco and alcohol.

The diagnosis of Psoriasis is primarily clinical and is based on the observation of elementary lesions in the form of well-limited erythematous-scaly spots, rounded, oval or polycyclic. Generally, Psoriasis is localized in the areas exposed to friction (elbows, knees, legs, low back region, scalp and nails). There are several clinical forms of Psoriasis, including scalp psoriasis, nail psoriasis, erythrodermic psoriasis, arthropathic psoriasis, pustular psoriasis or even psoriasis in children.

The evolution of Psoriasis is a chronic dermatosis and occurs by relapses interspersed with periods of remission of variable duration during which the lesions are generally minimal. These remissions are more frequent in summer because of the effect of ultraviolet rays. Flares, often unpredictable, are also sometimes triggered by psychological factors, stress, drugs, ENT infections or even a skin attack.

Note that Psoriasis is a frequent disease since it affects around 3 to 5% of the European population, this at all ages. If it is mostly a mild illness, Psoriasis can be disabling, especially for aesthetic reasons. As mentioned above, Psoriasis is caused by chronic inflammation of the skin, the precise origin of which, however, is not yet known. This inflammation leads to an important proliferation of epidermal cells, the keratinocytes which, instead of renewing themselves in 28 days, renew themselves in 3 days. This renewal

B E2017 / 5028 accelerated epidermis is accompanied by an abnormality of the cells which do not have time to properly finalize their normal maturation.

If the causes of an onset / remission of Psoriasis are not well determined to date, it is generally accepted that it is a multifactorial pathology and that at least the following factors are involved: inflammation , oxidation (oxidative stress) and the immune system. In addition, Psoriasis has a wide variety of phenotypes due to a complex and varied multifactorial combination of immunological mechanisms, a polygenic profile and cellular abnormalities in the skin.

Among the treatments for Psoriasis, a distinction is made between local treatments which are based on the use of dermocorticoids, analogs of vitamin D3 or on a combination of these two products. Dermocorticoids are generally used as an ointment or cream. However, these treatments are responsible for numerous and not insignificant side effects, which is why it is recommended to perform these treatments for a limited time and to closely monitor the quantities used. In addition, vitamin D analogs such as ca.lcipotriol (Daivonex), tacalcitoi (Apso / j and oeloitriol (S // x / s) exhibit slower activity than dermis-corticosteroids and may be responsible for '' skin irritations (in the face and in the folds of the skin).

Other topical treatments also exist such as baths and emollients used to strip lesions and relieve pruritus. Salicylic acid is also used (in a fatty excipient) to scour very scaly lesions but this is contraindicated in children (risk of sallcylated poisoning), Tazarotene (Zorac), a topical retinoid, is also used but an irritant effect can be observed and it is contraindicated in case of pregnancy,

Various phototherapies are also used to treat Psoriasis: PUVA therapy and UVB narrow spectrum phototherapy

2017/5028

B E2017 / 5028 (TL-01) at the rate of 3 sessions per week, which means that this therapy is restrictive.

If the treatments mentioned above prove to be ineffective, more general treatments are then applied and are carried out essentially by the oral intake of drugs of which there are four families:

~ your retinoids (derivatives of vitamin A synthesis) which are formally contraindicated in young women without effective contraception due to the risk of serious malformations in the fetus;

- methotrexate preventing the multiplication of cells. Regular monitoring of liver enzymes and white blood cells by blood test is necessary as well as a chest x-ray before starting treatment;

- Ciclosporin, an Immunosuppressant whose administration cannot be considered beyond a year or two at the most, because of the risks of renal damage. Its prescription requires monitoring of blood pressure and renal function; and

- biotherapies reserved for severe forms that have not responded to or having a contraindication to at least two other prior treatments including phototherapy, methotrexate and Ciclosporin,

These are treatments that require a certain number of examinations to be carried out before they are started, in particular an X-ray of the lungs and a tuberculin intradermal reaction to eliminate the existence of latent tuberculosis, as well than a blood test to rule out kidney failure and / or liver failure.

Biotherapies are more specifically anti-TNF or T lymphocyte aimed by inhibiting the LFA1-ICAM1 link,

In practice, it appears that current treatments are responsible for side effects such as dryness

B E2017 / 5028 mucocutaneous, scaling, hair loss, hepatic or pulmonary fibrosis, nephrotoxicity or even high blood pressure. More particularly, with regard to general treatments, it is advisable to resort to them exceptionally and to monitor them scrupulously in the light of significant side effects.

All the treatments mentioned above (local and general) therefore have certain limits on the one hand because of the significant side effects observed but also on the other hand because they do not intervene in a global manner on the three main causes recognized Psoriasis, that is to say on inflammation, on oxidative stress and on the immune system.

To date, there is therefore unfortunately no drug treatment proposing a composition intervening in a global and simultaneous manner on the three main recognized causes of Psoriasis, this without danger to health and by allowing at the same time an elimination of the symptoms and a decrease in the frequency of the acute phases of Psoriasis (remission of Psoriasis), there is therefore a real need to develop and formulate a composition for the treatment of Psoriasis, this composition being both harmless for health and effective for treat the three main recognized causes of Psoriasis comprehensively and simultaneously, in particular to reduce the frequency of remission of Psoriasis.

To solve this problem, there is provided according to the invention, a composition as indicated at the beginning, said composition comprising:

- at least one antioxidant, in particular at least one antioxidant of superoxide dismutase (SOD) type,

- Turmeric or at least one extract of Turmeric, in particular Curcuma longa or an extract of Turmeric longa, and

B E2017 / 5028

- from Boswellia or at least one Bosweliie extract, in particular Boswellia serrata or at least one extract from Boswellia serrata.

Turmeric (especially Turmeric longa) is known for its antioxidant properties helping the body to fight oxidative stress and maintain the effectiveness of natural defenses. It is also used as an anti-inflammatory and is arguably the most powerful natural anti-inflammatory identified to date.

Boswellia (in particular Boswellia serrata) is a tree whose resin constitutes a natural health product, in particular for treating inflammatory intestinal diseases (Crohn's disease, ...) or joints. The effects of Boswellia are linked to boswellic acids, compounds in the resin that can reduce inflammation.

In the context of the present invention, it has been surprisingly determined that the three constituents of the composition, namely at least one antioxidant, Turmeric or at least one extract of Turmeric and Boswellia or at least one extract of Boswellia, act in synergy so that the composition according to the invention treats in a global and simultaneous manner the three main recognized causes of Psoriasis, this without danger to health and by allowing at the same time an elimination of the symptoms and a reduction of the frequency of the acute phases of Psoriasis (remission of Psoriasis), It has therefore been determined that a composition according to the invention, in which each of the constituents is creative in a bio-available form, allows a global and simultaneous treatment of all the inflammatory pathways responsible for Psoriasis, this for several types of Psoriasis,

Advantageously, according to the invention, said at least one antioxidant, in particular said at least one antioxidant of superoxide dismutase (SOD) type, is present in an amount of 1% to 5% by weight relative to the total weight of the composition, preferably present in an amount of 1 to 3% by weight relative to the total weight of the composition.

B E2017 / 5028

Preferably, according to the invention, said turmeric or said at least one extract of turmeric is present in an amount of 10% to 50% by weight relative to the total weight of the composition, preferably present in an amount of 20% to 40% by weight relative to the total weight of the composition.

Preferably, according to the invention, said Boswellie or at least said Boswellie extract is present in an amount of 10% to 50% by weight relative to the total weight of the composition, preferably present in an amount of 20% to 30% by weight relative to the total weight of the composition.

Advantageously, the composition according to the invention also comprises krill or a krill extract in an amount of 20% to 80% by weight relative to the total weight of the composition, preferably present in an amount of 25% to 55% by weight. relative to the total weight of the composition.

Preferably, according to the invention, said at least one antioxidant is chosen from the group consisting of superoxide dismutase (SOD), N ~ acetylcysine, vitamin C, vitamin E, D ~ o ~ tocopherol, Do- tocopheryl acetate, choline, zinc citrate, seienomethionione, glutathione and their mixtures.

More preferably, said at least one antioxidant is superoxide dismutase (SOD),

Advantageously, the composition according to the invention also comprises at least one pharmaceutically acceptable excipient chosen from the group consisting of microcrystalline cellulose, magnesium stearate and their mixtures.

Preferably, the composition according to the invention is in the form of a food supplement.

Preferably, the composition according to the invention is in a form which can be administered orally, for example in the form of a tablet, a capsule, a capsule, a cachet, a

2017/5028

B E2017 / 5028 soluble powder, a drink, an oily solution, an effervescent tablet or a soft capsule.

Preferably, the composition according to the invention is administered at the rate of 1 to 2 capsules per day in adults.

Other embodiments of a composition according to the invention are indicated in the appended claims.

Other characteristics, details and advantages of the invention will emerge from the example given below without implied limitation.

Example eFune composition according to the Invention

The table below is an example of a composition according to the invention in the form of a tablet.

** N.D. ~ not determined

It is understood that the present invention is in no way limited to the embodiments described above and that many modifications can be made without departing from the scope of the appended claims.

B E2017 / 5028

Claims (10)

1. Composition intended for use in the treatment of Psoriasis, said composition comprising: at least one antioxidant, in particular at least one antioxidant of superoxide dismutase (SOD) type, - Turmeric or at least one extract of Turmeric, in particular Curcuma longa or an extract of Turmeric longa, and - Boswellia or at least one Boswellia extract, in particular Boswellia serrate or at least one Boswellia serrate extract. 2. Composition intended for use according to claim 1, in which said at least one antioxidant, in particular said at least one antioxidant of superoxide dismutase type (SOD), is present in an amount of 1% to 5% by weight relative to the total weight of the composition, preferably present at a rate of 1% to 3% by weight relative to the total weight of the composition, 3. Composition for use according to claim 1 or 2, wherein said Turmeric or said at least one extract of Turmeric is present in an amount of 10% to 50% by weight relative to the total weight of the composition, preferably present at a rate of 20% to 40% by weight relative to the total weight of the composition. 4. Composition intended to be used according to any one of claims 1 to 3, in which said Boswellie or at least said Boswellie extract is present in an amount of 10% to 50% by weight relative to the total weight of the composition, preferably present in an amount of 20% to 30% by weight relative to the total weight of the composition. 5. Composition intended to be used according to any one of claims 1 to 4, further comprising krill or an extract of krill in an amount of 20% to 60% by weight relative to the total weight of the composition, preferably present in the right from 25% to 55% by weight relative to the total weight of the composition. 2017/5028 B E2017 / 5028 6. Composition intended to be used according to any one of claims 1 to 5, in which said at least one antioxidant is chosen from the group consisting of superoxide dismutase (SOD), N5 acetylcysteine, vitamin C, vitamin E , Da-tocopherol, D ~ a ~ tocopheryl acetate, choline, zinc citrate, selenomethionione, glutathione and their mixtures. 7. Composition for use according to any one of claims 1 to 6, further comprising at least one excipient 10 pharmaceutically acceptable chosen from the group consisting of microcrystalline cellulose, magnesium stearate and their mixtures, 8. Composition intended to be used according to any one of claims 1 to 7, said composition being in the form of a food supplement. 15 9. Composition intended to be used according to any one of claims 1 to 8, said composition being in a form which can be administered orally, for example under the firmness of a tablet, a capsule, a capsule, a cachet, a soluble powder, a drink, an oily solution, an effervescent tablet or a soft capsule. 10. Composition for use) according to any one of claims 1 to 9, said composition being administered at a rate of 1 to 2 capsules per day in adults. 2017/5028 B E2017 / 5028 SHORT Composition for use in the treatment of Psoriasis The present invention relates to a composition intended to be used in the treatment of Psoriasis, said composition comprising: - at least one antioxidant, in particular at least one antioxidant of superoxide dismutase (SOD) type, - Turmeric or at least one extract of Turmeric, in particular 10 Turmeric Ionga or an extract of Turmeric tonga, and - from Bosweilie or at least one extract from Bosweilto, in particular Bosweliia serrata or at least one extract from Bosweliia serra ta. PATENT COOPERATION TREATY